medicine-technology-1/royal-institute-of-technology-adopts-origene-over-expression-lysates-in-human-proteome-atlas-program-6098-1/;+health+history;+medical+history.html

Breaking Biology Technology:WuXi PharmaTech Selects Labcyte POD(TM) 810 Platform for High-Throughput Screening 2 NIST researchers put a new spin on atomic musical chairs 2 Stemline Therapeutics Announces Poster Presenting in vivo and Anti-Cancer Stem Cell Activity of SL-401 against Chronic Myeloid Leukemia (CML) at the 51st Annual Meeting of the American Society of Hematology (ASH) 2 Nikon Corporation Acquires License From Harvard University For 'STORM' Super Resolution Microscopy -- Will Create Innovative New 'N-STORM' Microscope 2 Nikon Corporation Acquires License From Harvard University For 'STORM' Super Resolution Microscopy -- Will Create Innovative New 'N-STORM' Microscope 3

[0] WuXi PharmaTech Selects Labcyte POD(TM) 810 Platform for High-Throughput Screening [0] NIST researchers put a new spin on atomic musical chairs [0] Stemline Therapeutics Announces Poster Presenting in vivo and Anti-Cancer Stem Cell Activity of SL-401 against Chronic Myeloid Leukemia (CML) at the 51st Annual Meeting of the American Society of Hematology (ASH)[0] Nikon Corporation Acquires License From Harvard University For 'STORM' Super Resolution Microscopy -- Will Create Innovative New 'N-STORM' Microscope

Breaking Medicine Technology:ChemoCentryx Reports Additional New Data from the PROTECT-1 Study Demonstrating Traficet-EN's Effectiveness in Maintaining Remission in Patients with Crohn's Disease 2 ChemoCentryx Reports Additional New Data from the PROTECT-1 Study Demonstrating Traficet-EN's Effectiveness in Maintaining Remission in Patients with Crohn's Disease 3 ChemoCentryx Reports Additional New Data from the PROTECT-1 Study Demonstrating Traficet-EN's Effectiveness in Maintaining Remission in Patients with Crohn's Disease 4 ChemoCentryx Reports Additional New Data from the PROTECT-1 Study Demonstrating Traficet-EN's Effectiveness in Maintaining Remission in Patients with Crohn's Disease 5 ChemoCentryx Reports Additional New Data from the PROTECT-1 Study Demonstrating Traficet-EN's Effectiveness in Maintaining Remission in Patients with Crohn's Disease 6 ChemoCentryx Reports Additional New Data from the PROTECT-1 Study Demonstrating Traficet-EN's Effectiveness in Maintaining Remission in Patients with Crohn's Disease 7 CompuCyte Announces the Release of Four-Laser Imaging Cytometers 2 Stallergenes: Oralair: Very Positive 3-Year Results of the Long-Term Study 2 Stallergenes: Oralair: Very Positive 3-Year Results of the Long-Term Study 3 Stallergenes: Oralair: Very Positive 3-Year Results of the Long-Term Study 4 Stallergenes: Oralair: Very Positive 3-Year Results of the Long-Term Study 5 MedicAlert Foundation International and CAP STS Collaborate to Standardize Emergency Medical Information 59051 1 MedicAlert Foundation International and CAP STS Collaborate to Standardize Emergency Medical Information 59051 2 MedicAlert Foundation International and CAP STS Collaborate to Standardize Emergency Medical Information 59051 3 MedicAlert Foundation International and CAP STS Collaborate to Standardize Emergency Medical Information 59051 4 Purolator USA Offers Advanced Tracking Capabilities for Medical Device Shipments 59046 1 Purolator USA Offers Advanced Tracking Capabilities for Medical Device Shipments 59046 2 Purolator USA Offers Advanced Tracking Capabilities for Medical Device Shipments 59046 3 Free Pills from Government Boost Potassium Iodide Sales 59040 1 Free Pills from Government Boost Potassium Iodide Sales 59040 2

[0] ChemoCentryx Reports Additional New Data from the PROTECT-1 Study Demonstrating Traficet-EN's Effectiveness in Maintaining Remission in Patients with Crohn's Disease [0] CompuCyte Announces the Release of Four-Laser Imaging Cytometers [0] Stallergenes: Oralair: Very Positive 3-Year Results of the Long-Term Study